If you’re searching for some new blue chip shares to add to your portfolio, then the two listed below could be worthy candidates.
These blue chip ASX 200 shares have strong business models and positive growth outlooks.
Even better, though, is that they have recently been named as buys by analysts:
Goodman Group (ASX: GMG)
The first blue chip ASX 200 share to look at is this integrated commercial and industrial property company.
Goodman could be a top option due to its world class portfolio, which comprises warehouses, data centres, large scale logistics facilities, and business and office parks.
Demand for its properties has been very strong, leading to sky high occupancy rates and stellar earnings growth over the last decade. This is being driven by its strategy of developing modern, high quality properties in key gateway cities around the world.
Morgan Stanley is a fan of the company. It currently has an overweight rating and $26.50 price target on Goodman’s shares.
Healius Ltd (ASX: HLS)
Another blue chip ASX 200 share to look at is Healius. It is one of Australia’s largest pathology and diagnostic imaging providers offering services via a number of brands. These include Dorevitch Pathology, QML Pathology, Laverty Pathology, and Healthcare Imaging Services.
It also just added to this last week with the acquisition of Agilex for an enterprise value of $301.3 million. Agilex is one of Australia’s leading bioanalytical laboratories.
This acquisition is expected to be accretive to the company’s earnings, which have already been growing strongly in FY 2022.
For example, for the first quarter of FY 2022, Healius reported a 43.7% increase in group quarterly revenue over the prior corresponding period to $689.9 million. This was driven by strong demand for COVID testing and a robust performance from the rest of the business.
Macquarie is bullish on Healius. It currently has an outperform rating and $5.65 price target on the company’s shares.